Market revenue in 2019 | USD 31.1 million |
Market revenue in 2027 | USD 74.9 million |
Growth rate | 11.6% (CAGR from 2019 to 2027) |
Largest segment | Subcutaneous immunotherapy |
Fastest growing segment | Sublingual immunotherapy |
Historical data | 2016 - 2018 |
Base year | 2019 |
Forecast period | 2020 - 2027 |
Quantitative units | Revenue in USD million |
Market segmentation | Subcutaneous immunotherapy, Sublingual immunotherapy |
Key market players worldwide | Merck KGaA, Allergy Therapeutics PLC, DBV Technologies SA ADR, ASIT biotech, Circassia, Mylan, DMK Pharmaceuticals Corp, Alk-Abello A/S Class B, Desentum, HAL Allergy Group, HollisterStier Allergy, Stallergenes Greer |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to allergy immunotherapy market will help companies and investors design strategic landscapes.
Subcutaneous immunotherapy was the largest segment with a revenue share of 84.24% in 2019. Horizon Databook has segmented the Japan allergy immunotherapy market based on subcutaneous immunotherapy, sublingual immunotherapy covering the revenue growth of each sub-segment from 2016 to 2027.
Horizon Databook provides a detailed overview of country-level data and insights on the Japan allergy immunotherapy market, including forecasts for subscribers. This country databook contains high-level insights into Japan allergy immunotherapy market from 2016 to 2027, including revenue numbers, major trends, and company profiles.
No related regions found.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account